Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols

Table 2 Histopathologic assessment of various antiarthritic agents in the Tg197 murine model of rheumatoid arthritis

		% of total at indicated HS scores
Treatment	Joints scored	HS 0	HS 1	HS 2	HS 3	HS 4	Mean HS ± standard error
Untreated	20	0	0	20	30	50	3.30 ± 0.18
WFI	20	0	0	15	50	35	3.20 ± 0.15
Diacerein 2 mg/kg daily	18	5	23	50	11	11	2.00 ± 0.24*
Diacerein 20 mg/kg daily	16	6	19	25	44	6	2.25 ± 0.26*
Diacerein 60 mg/kg daily	20	5	15	35	20	25	2.45 ± 0.26*
Methotrexate 1 mg/kg three times weekly	12	0	0	8	25	67	3.58 ± 0.19
Dexamethasone 0.5 mg/kg daily	12	25	67	8	0	0	0.83 ± 0.16*
CB0006 5 mg/kg weekly	12	100	0	0	0	0	0*

Histopathogic score (HS) was evaluated on ankle joints of untreated or treated Tg197 mice at age 7 weeks. In the case of the methotrexate, dexamethasone, and anti-tumor necrosis factor antibody treatments, the data shown are derived from one representative from three independent experiments. *P < 0.05 versus untreated or water for injection (WFI) treated Tg197 control groups.

ISSN: 1478-6362